Dynavax Technologies Corporation $DVAX Shares Purchased by Woodline Partners LP

Key Points

• Woodline Partners LP increased its stake in Dynavax Technologies Corporation by 48.4%, holding approximately 1,178,763 shares valued at $15.29 million.
• Dynavax reported a quarterly EPS of $0.14, surpassing estimates and generating revenue of $95.44 million, which was higher than the expected $87.55 million.
• Wall Street analysts have upgraded their ratings on Dynavax, with a consensus price target of $24.33, indicating a positive outlook for the company's stock.

Woodline Partners LP lifted its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 48.4% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,178,763 shares of the biopharmaceutical company's stock after buying an additional 384,288 shares during the period. Woodline Partners LP owned about 0.98% of Dynavax Technologies worth $15,289,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. DekaBank Deutsche Girozentrale purchased a new position in shares of Dynavax Technologies during the 1st quarter worth about $30,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Dynavax Technologies by 5,485.7% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 2,346 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 2,304 shares during the period. GF Fund Management CO. LTD. purchased a new position in shares of Dynavax Technologies during the 4th quarter worth about $35,000. GAMMA Investing LLC boosted its stake in shares of Dynavax Technologies by 88.4% during the 1st quarter. GAMMA Investing LLC now owns 7,729 shares of the biopharmaceutical company's stock worth $100,000 after purchasing an additional 3,627 shares during the period. Finally, Moloney Securities Asset Management LLC purchased a new position in shares of Dynavax Technologies during the 1st quarter worth about $131,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Price Performance

DVAX traded up $0.26 during midday trading on Tuesday, hitting $9.62. 611,004 shares of the company traded hands, compared to its average volume of 2,063,500. The company has a current ratio of 6.65, a quick ratio of 6.01 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -20.90 and a beta of 1.24. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $14.63. The business has a 50 day simple moving average of $10.57 and a two-hundred day simple moving average of $11.03.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.02. The business had revenue of $95.44 million for the quarter, compared to the consensus estimate of $87.55 million. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. On average, equities analysts forecast that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

DVAX has been the subject of several research reports. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities reissued a "market outperform" rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.33.

Insider Buying and Selling at Dynavax Technologies

In other Dynavax Technologies news, Director Scott Dunseth Myers purchased 3,800 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were purchased at an average cost of $10.82 per share, with a total value of $41,116.00. Following the completion of the purchase, the director owned 35,004 shares in the company, valued at approximately $378,743.28. This represents a 12.18% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 2.98% of the company's stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.